Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Timothy Eugene Sullivan, the Chief Financial Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold 3,088 shares of the company’s common stock. The transaction, which took place on ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million ...